NR2F6 deletion boosts CAR-T activity against solid tumors
Nature Communications findings showed NR2F6 deletion revived exhausted CAR-T cells and boosted activity against solid tumors. In murine models, modified cells drove tumor regression, prolonged survival and resistance to rechallenge.
NR2F6 deletion enhanced CAR-T cell efficacy against solid tumors in findings published in Nature Communications. Researchers said deletion of the nuclear receptor revived fatigued CAR-T cell functionality and fostered antigen-agnostic immune memory, with significant tumor regression and prolonged survival in murine models of glioblastoma and pancreatic adenocarcinoma.
Chimeric Antigen Receptor T-cell therapy has yielded remarkable remission rates in hematologic cancers, but its extension to solid tumors has been hindered by tumor heterogeneity, antigen escape, and an immunosuppressive tumor microenvironment that impedes T cell persistence and functionality. The study focused on NR2F6, an intracellular immune checkpoint that negatively regulates T cell activation and effector functions.
Researchers used gene-editing techniques to excise NR2F6 in engineered CAR-T cells targeting diverse solid tumor antigens. The modification induced a phenotypic rejuvenation of exhausted CAR-T cells, with enhanced proliferation, increased cytokine secretion, and resistance to suppressive metabolic cues within the tumor microenvironment.
The modified cells showed profound cytotoxicity in antigen-positive tumor cells and also demonstrated cross-reactive killing capacity independent of the original CAR specificity, described as antigen-agnostic immune memory. Mechanistically, NR2F6 deletion elevated expression of pro-inflammatory cytokines such as IFN-γ and TNF-α while suppressing inhibitory pathways linked to cellular exhaustion and metabolic dysregulation.
In vivo models showed that NR2F6-deficient CAR-T cells achieved significant tumor regression and prolonged survival in aggressive cancers including glioblastoma and pancreatic adenocarcinoma. Treated subjects also exhibited resistance to tumor rechallenge, underscoring the establishment of a long-lived, antigen-agnostic immune memory.
The safety evaluation showed no overt signs of systemic autoimmunity or off-target tissue damage. The findings said this work charts a roadmap for next-generation CAR-T cell design, integrating gene editing to remove intrinsic inhibitory checkpoints like NR2F6 alongside antigen targeting modules.